In vivo studies in xenograft models of ovarian, cervical, breast, gastric, colorectal, liver and lung cancers as well as neuroblastoma and osteosarcoma have shown the efficacy of NORAD-targeting therapeutic options in reducing tumor burden. The gene discussed is NORAD; the disease is neoplasm.